The use of non-hypoxic cell sensitizers in radiobiology and radiotherapy.
Many different non-hypoxic cell radiosensitizers have been identified over the years. Radiosensitization by these agents is mediated through a variety of mechanisms, including inhibition of repair (both enzymatic and chemical), modification in the DNA molecule, and perturbation and redistribution in the cell cycle. Recent clinical interest in the use of halogenated pyrimidines as radiosensitizers has prompted a number of questions requiring both laboratory and clinical research to maximize this therapeutic approach. Other radiosensitizers that alter cellular redox processes in different ways are discussed in the context of better understanding the cellular biochemical systems that are affected in aerobic radiosensitization. Advancement in the use of non-hypoxic cell sensitizers in radiation cancer treatment will most likely depend on a knowledge of the detailed biochemical mechanisms of these agents and how they might be used to exploit any subtle biochemical differences between tumor and normal tissue.
D000818:Animals; D001973:Bromodeoxyuridine / Q000627:therapeutic use; D019328:Buthionine Sulfoximine; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D006224:Cricetinae; D004260:DNA Repair / Q000187:drug effects; D003958:Diamide / Q000627:therapeutic use; D005978:Glutathione / Q000502:physiology; D006801:Humans; D007065:Idoxuridine / Q000627:therapeutic use; D066298:In Vitro Techniques; D008717:Methionine Sulfoximine / Q000031:analogs & derivatives / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology*
D011838:Radiation-Sensitizing Agents; D003958:Diamide; D008717:Methionine Sulfoximine; D019328:Buthionine Sulfoximine; D001973:Bromodeoxyuridine; D005978:Glutathione; D007065:Idoxuridine